Davita Inc (NYSE:DVA) – Equities research analysts at William Blair dropped their Q3 2020 earnings per share (EPS) estimates for Davita in a research note issued on Wednesday, November 6th. William Blair analyst M. Larew now forecasts that the company will post earnings of $1.37 per share for the quarter, down from their previous estimate of $1.39. William Blair has a “Market Perform” rating on the stock. William Blair also issued estimates for Davita’s Q4 2020 earnings at $1.44 EPS.
Davita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $1.53 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.24 by $0.29. The business had revenue of $2.90 billion for the quarter, compared to the consensus estimate of $2.85 billion. Davita had a return on equity of 18.03% and a net margin of 3.68%. The firm’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.56 earnings per share.
Other equities research analysts also recently issued research reports about the company. Robert W. Baird downgraded Davita from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $70.00 to $65.00 in a research report on Friday, July 26th. Wolfe Research downgraded Davita from an “outperform” rating to a “market perform” rating and set a $57.00 price target on the stock. in a research report on Friday, October 25th. SunTrust Banks increased their price target on Davita to $72.00 and gave the stock a “hold” rating in a research report on Wednesday. TheStreet raised Davita from a “c+” rating to a “b-” rating in a research report on Wednesday, July 24th. Finally, UBS Group reduced their price target on Davita from $61.00 to $60.00 and set a “neutral” rating on the stock in a research report on Thursday, August 22nd. Nine investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $64.81.
Shares of NYSE:DVA opened at $69.85 on Friday. The company has a market capitalization of $10.01 billion, a P/E ratio of 19.57, a P/E/G ratio of 0.62 and a beta of 1.59. Davita has a 1 year low of $43.40 and a 1 year high of $70.51. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.12 and a quick ratio of 1.10. The business’s 50 day simple moving average is $58.51 and its 200 day simple moving average is $55.70.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Benjamin F. Edwards & Company Inc. bought a new stake in Davita during the third quarter worth $68,000. SG Americas Securities LLC lifted its stake in Davita by 1.2% during the third quarter. SG Americas Securities LLC now owns 35,728 shares of the company’s stock worth $2,039,000 after purchasing an additional 441 shares during the last quarter. Tibra Equities Europe Ltd bought a new stake in Davita during the third quarter worth $1,141,000. Creative Planning lifted its stake in Davita by 33.8% during the third quarter. Creative Planning now owns 9,672 shares of the company’s stock worth $552,000 after purchasing an additional 2,441 shares during the last quarter. Finally, IFM Investors Pty Ltd lifted its stake in Davita by 38.7% during the third quarter. IFM Investors Pty Ltd now owns 11,595 shares of the company’s stock worth $662,000 after purchasing an additional 3,234 shares during the last quarter. Hedge funds and other institutional investors own 91.00% of the company’s stock.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Recommended Story: What is the Rule of 72?
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.